Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff

Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions

Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis

Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.

Revolutionizing Biotherapeutic Analysis: Novel icIEF Fractionation and Mass Spectrometry for Charge Characterization

biotherapeutics, icIEF fractionation, mass spectrometry, charge characterization, protein analysis, therapeutic proteins, biopharmaceuticals, analytical techniques, protein purification, protein separation, protein charge variants.